The American Journal of Medicine
Volume 116, Issue 6, Supplement 1 , Pages 3-8 , 22 March 2004

Past, present, and future standards for management of dyslipidemia

  • John C LaRosa, MD

      Affiliations

    • State University of New York Health Science Center, Brooklyn, New York, USA, and Weill Medical College of Cornell University, New York, New York, USA
    • Corresponding Author InformationRequests for reprints should be addressed to John C. LaRosa, MD, State University of New York, Health Science Center at Brooklyn, 450 Clarkson Avenue, Box 1, Brooklyn, New York 11203, USA.
    • ,
  • Antonio M Gotto Jr, MD, DPhil

      Affiliations

    • State University of New York Health Science Center, Brooklyn, New York, USA, and Weill Medical College of Cornell University, New York, New York, USA

References 

  1. Expert Panel . Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148:36–69
  2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015–3023
  3. National Cholesterol Education Program . Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1329–1445
  4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III Final Report). Circulation. 2002;106:3143–3421
  6. Goff DC, Labarthe DR, Howard G, Russell GB. Primary prevention of high blood cholesterol concentrations in the United States. Arch Intern Med. 2002;162:913–919
  7. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease (a meta-analysis of randomized controlled trials). JAMA. 1999;282:2340–2346
  8. Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol. 1998;82:3Q–12Q
  9. Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  10. Jones PH. Low-density lipoprotein cholesterol reduction and cardiovascular disease prevention (the search for superior treatment). Am J Med. 2004;Vol 116(suppl 6A):18S–27S
  11. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565
  12. Libby P, Ridker PM. Inflammation and atherosclerosis (role of C-reactive protein in risk assessment). Am J Med. 2004;116(suppl 6A):9S–16S
  13. Pearson TA, Mensah GA, Alexander RW, et al.  Markers of inflammation and cardiovascular disease. Application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511
  14. O'Leary DH, Polak JF, Kronmal RA. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14–22
  15. O'Leary DH, Polak JF. Intima-media thickness (a tool for atherosclerosis imaging and event prediction). Am J Cardiol. 2002;90:18L–21L
  16. Kondos GT, Hoff JA, Sevrukov A, et al.  Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation. 2003;107:2571–2576
  17. Lakka H-M, Laaksonen DE, Lakka TA, et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–2716
  18. Ballantyne CM, Olsson AG, Cook TJ. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104:3046–3051
  19. Durrington PN, Prais H, Bhatnagar D, et al.  Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet. 1999;353:278–281

PII: S0002-9343(04)00071-3

doi: 10.1016/j.amjmed.2004.02.005

The American Journal of Medicine
Volume 116, Issue 6, Supplement 1 , Pages 3-8 , 22 March 2004

Article Tools

* Image Usage & Resolution